---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-026712"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2024-02-07T23:59:59+00:00"
generated_at: "2026-06-06T07:14:58.901028+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Terns Pharmaceuticals appoints Amy Burroughs as CEO and director effective Feb 7, 2024

## Summary
- Amy Burroughs appointed CEO effective Feb 7, 2024; Jill Quigley becomes independent director after serving as Interim Senior Advisor.
- Burroughs receives $625k salary, 50% target bonus, option to buy 1.25M shares, and 150k RSUs with price milestones at $15 and $20.
- Burroughs previously CEO of Cleave Therapeutics, brings over 25 years experience in biotech and commercial roles.
- Equity awards previously granted to Quigley will continue to vest based on her director service.

## SEC filing metadata
- accession: 0001193125-24-026712
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2024-02-07T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000119312524026712/0001193125-24-026712-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000119312524026712/d718313d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-026712
- JSON: https://secwatch.observer/filing/0001193125-24-026712.json
- Plain text: https://secwatch.observer/filing/0001193125-24-026712.txt

## Key facts
- Executive change
  Amy Burroughs was appointed as Chief Executive Officer and Director at Terns Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Executive Officer and Director
  source text: pursuant to which Ms. Burroughs will serve as the Chief Executive Officer of Terns and has been appointed and elected as a member of the Board of Directors of Terns (the “Board”), effective as of February 7, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831363/000119312524026712/0001193125-24-026712-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.